iconiifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Q3FY24 Review: Zydus Lifesciences: Near-term benefit of delayed Asacol competition

12 Feb 2024 , 02:37 PM

Recommendation: Buy; Target price: ₹885

Zydus’ Q3 performance was largely in-line with analysts of IIFL Securities estimates, with base business Ebitda margins (ex-Revlimid) sustaining at ~24%. While US revenue missed analysts of IIFL Securities estimates by 5%, India growth was strong at 16% YoY driven by MS gains in Diabetes/Anti-Infectives segments and robust traction in the Innovation portfolio in the domestic market. With Zydus targeting 1-2 sizeable launches in the US every year till 2027 and double-digit growth in India, analysts of IIFL Securities expect the company’s base business (ex-Revlimid) to clock 8/9% revenue/EPS Cagr over FY24-27. Analysts of IIFL Securities now factor-in Asacol HD competition from Q4FY25 vs their earlier assumption of Q4FY24, which along with 100-150bps higher margins p.a., has driven 4-7% Ebitda upgrades for FY25/26. Analysts of IIFL Securities maintain theur ADD rating and their TP of ₹885 (10% upside) is pegged at ~26x FY26 core EPS (exRevlimid) and Rs22 NPV/share for Revlimid.

 Zydus has 1-2 sizeable opportunities in the US every year till 2027, with majority of these being settled products. One example of this is the recent in-licensing deal for Ibrance (Palbociclib) on which Zydus will have FTF launch likely in Mar’27, with potential exclusivity revenue of USD80- 100m, assuming 25-30% revenue share for Zydus. In the near-term, Revlimid will contribute in Q4/Q1 every fiscal year, with increasing contribution in FY25. Sitagliptin 505(b)2 opportunity will scale-up gradually in FY25, while transdermals could become a USD50-60m portfolio for Zydus over the next 2-3 years. On the back of 15-20 launches p.a. and Revlimid scale-up, analysts of IIFL Securities expect US sales to increase +10/+3/-8% cc over FY25-27. Asacol and Revlimid erosion will be hurting growth in FY26/27 resp. 

Analysts of IIFL Securities expect 11% Cagr in Zydus’ India business over FY24-27, driven by further scale-up in the Chronic portfolio (currently 41% revenue share) and Specialty products. While Q3 growth for Zydus was strong, analysts of IIFL Securities note that as per secondary data Zydus’ India business has grown at 10% Cagr over CY20-23, slightly below IPM growth of 11.5% Cagr. Zydus’ India volumes have been flat over the past 3 years vs IPM volume growth of 3% Cagr and price increases have contributed ~57% to Zydus’ India growth. 

Analysts of IIFL Securities assume Zydus’ core Ebitda margins (ex-Revlimid) to moderate slightly to 22-22.5% over FY25-27 vs 23-24% currently, owing to incremental competition in Asacol HD and increasing R&D spends for the NCE innovation portfolio. However, Revlimid contribution will ensure that overall Ebitda margins sustain at ~27% over FY24-26.

Related Tags

  • Zydus Lifesciences
sidebar mobile


19 Feb 2024   |   09:29 AM
Read More
Knowledge Centerplus

Logo IIFL Customer Care Number
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Knowledge Centerplus

Follow us on


2024, IIFL Securities Ltd. All Rights Reserved

  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.